Literature DB >> 971476

Physiological disposition of verapamil in man.

M Schomerus, B Spiegelhalder, B Stieren, M Eichelbaum.   

Abstract

14C-D,L-verapamil was administered intravenously (10 mg) and orally (80 mg) to five volunteer patients. Plasma concentrations of verapamil, which were determined by mass fragmentography, declined bi-exponentially with half-lives of the chi-phase ranging from 18 to 35 min and of the beta-phase from 170 to 440 min. The apparent volume of distribution ranged from 270 to 460 litre and plasma clearance from 730 to 1980 ml/min. Following oral administration absorption was almost complete as judged from the area under the curve (AUC) of 14C-activity and cumulative urinary excretion of 14C. After intravenous infusion of verapamil about 80% of the radioactivity administered could be recovered in urine and faeces within 5 d. Despite its almost complete absorption after oral administration verapamil was shown to undergo extensive first pass metabolism as the bioavailability was only 10 to 22%. Rapid biotransformation had occurred as only a small percentage of AUC of 14C was seen to correspond to unchanged verapamil after both intravenous and oral administration.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 971476     DOI: 10.1093/cvr/10.5.605

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  50 in total

1.  Pharmacokinetics and pharmacodynamics of verapamil following sublingual and oral administration to healthy volunteers.

Authors:  D N John; S Fort; M J Lewis; D K Luscombe
Journal:  Br J Clin Pharmacol       Date:  1992-06       Impact factor: 4.335

2.  Spline functions in convolutional modeling of verapamil bioavailability and bioequivalence. II: study in healthy volunteers.

Authors:  J Popović; R Mitić; A Sabo; M Mikov; V Jakovljević; K Daković-Svajcer
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2006 Apr-Jun       Impact factor: 2.441

3.  Validation of the hepatic blood flow rate model for verapamil first-pass metabolism.

Authors:  Jovan Popović
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2007 Jan-Mar       Impact factor: 2.441

4.  Circadian variation in the pharmacokinetics of verapamil.

Authors:  C M Jespersen; M Frederiksen; J F Hansen; N A Klitgaard; C Sørum
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

5.  Serum binding of nifedipine and verapamil in patients with ischaemic heart disease on monotherapy.

Authors:  D O Rumiantsev; V K Piotrovskii; V I Metelitsa; I D Slastnikova; E V Kokurina
Journal:  Br J Clin Pharmacol       Date:  1989-09       Impact factor: 4.335

6.  Absolute bioavailability of imipramine: influence of food.

Authors:  D R Abernethyl; M Divoll; D J Greenblatt; J S Harmatz; R I Shader
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

Review 7.  Pharmacokinetic and pharmacodynamic considerations in drug therapy of cardiac emergencies.

Authors:  P Pentel; N Benowitz
Journal:  Clin Pharmacokinet       Date:  1984 Jul-Aug       Impact factor: 6.447

8.  Verapamil pharmacokinetics and apparent hepatic and renal blood flow.

Authors:  P A Meredith; H L Elliott; F Pasanisi; A W Kelman; D J Sumner; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1985-08       Impact factor: 4.335

9.  Pharmacokinetic interaction between oral lovastatin and verapamil in healthy subjects: role of P-glycoprotein inhibition by lovastatin.

Authors:  Dong-Hyun Choi; Joong-Hwa Chung; Jun-Shik Choi
Journal:  Eur J Clin Pharmacol       Date:  2009-12-12       Impact factor: 2.953

10.  Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis.

Authors:  A Somogyi; M Albrecht; G Kliems; K Schäfer; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1981-07       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.